ViGenCell（A308080）株式概要バイジェンセル社は免疫細胞療法を専門としている。 詳細A308080 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6リスク分析収益が 100 万ドル未満 ( ₩279M )KR市場と比較して、過去 3 か月間の株価の変動が非常に大きい最新の財務報告は1年以上前のものである 意味のある時価総額がありません ( ₩145B )すべてのリスクチェックを見るA308080 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩7.09k16.5k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-18b279m2016201920222025202620282031Revenue ₩278.9mEarnings ₩51.3mAdvancedSet Fair ValueView all narrativesViGenCell Inc. 競合他社NeoImmuneTechSymbol: KOSDAQ:A950220Market cap: ₩154.8bTiumBioSymbol: KOSDAQ:A321550Market cap: ₩122.9bPrestige BiologicsSymbol: KOSDAQ:A334970Market cap: ₩140.0bBio SolutionLtdSymbol: KOSDAQ:A086820Market cap: ₩168.0b価格と性能株価の高値、安値、推移の概要ViGenCell過去の株価現在の株価₩7,090.0052週高値₩17,360.0052週安値₩2,765.00ベータ1.721ヶ月の変化-26.68%3ヶ月変化18.17%1年変化139.53%3年間の変化2.90%5年間の変化n/aIPOからの変化-76.17%最新ニュースNew Risk • Jun 19New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩149.4b (US$97.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2025 fiscal period end). Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$181k). Minor Risk Market cap is less than US$100m (₩149.4b market cap, or US$97.1m).New Risk • May 16New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2025. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2025 fiscal period end). Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$186k).お知らせ • Feb 27ViGenCell Inc., Annual General Meeting, Mar 26, 2026ViGenCell Inc., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 222, banpo-daero, seocho-gu, seoul South KoreaNew Risk • Feb 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩125.7b (US$87.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$193k). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (₩125.7b market cap, or US$87.1m).New Risk • Dec 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$190k). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (₩125.6b market cap, or US$85.5m).New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩279m revenue, or US$189k). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩93.1b market cap, or US$63.2m).最新情報をもっと見るRecent updatesNew Risk • Jun 19New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩149.4b (US$97.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2025 fiscal period end). Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$181k). Minor Risk Market cap is less than US$100m (₩149.4b market cap, or US$97.1m).New Risk • May 16New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2025. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2025 fiscal period end). Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$186k).お知らせ • Feb 27ViGenCell Inc., Annual General Meeting, Mar 26, 2026ViGenCell Inc., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 222, banpo-daero, seocho-gu, seoul South KoreaNew Risk • Feb 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩125.7b (US$87.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$193k). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (₩125.7b market cap, or US$87.1m).New Risk • Dec 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$190k). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (₩125.6b market cap, or US$85.5m).New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩279m revenue, or US$189k). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩93.1b market cap, or US$63.2m).New Risk • Oct 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$197k). Minor Risk Market cap is less than US$100m (₩73.0b market cap, or US$51.5m).分析記事 • Jul 15Does ViGenCell (KOSDAQ:308080) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Risk • Jul 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩279m revenue, or US$203k). Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$100m (₩77.7b market cap, or US$56.4m).分析記事 • Feb 28Is ViGenCell (KOSDAQ:308080) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...お知らせ • Feb 27ViGenCell Inc., Annual General Meeting, Mar 27, 2025ViGenCell Inc., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 222, banpo-daero, seocho-gu, seoul South Koreaお知らせ • Jan 25Gaeun Global Co.,Ltd completed the acquisition of 11.36% stake in ViGenCell Inc. (KOSDAQ:A308080) from Boryung Corporation (KOSE:A003850).Gaeun Global Co.,Ltd agreed to acquire 11.36% stake in ViGenCell Inc. (KOSDAQ:A308080) from Boryung Corporation (KOSE:A003850) for KRW 7.9 billion on December 18, 2024. Gaeun Global Co.,Ltd completed the acquisition of 11.36% stake in ViGenCell Inc. (KOSDAQ:A308080) from Boryung Corporation (KOSE:A003850) on January 23, 2025.New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩56m revenue, or US$39k). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩65.3b market cap, or US$46.0m).分析記事 • Nov 15Is ViGenCell (KOSDAQ:308080) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jul 25Is ViGenCell (KOSDAQ:308080) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...株主還元A308080KR BiotechsKR 市場7D-11.2%0.2%10.0%1Y139.5%9.1%179.8%株主還元を見る業界別リターン: A308080過去 1 年間で9.1 % の収益を上げたKR Biotechs業界を上回りました。リターン対市場: A308080は、過去 1 年間で179.8 % のリターンを上げたKR市場を下回りました。価格変動Is A308080's price volatile compared to industry and market?A308080 volatilityA308080 Average Weekly Movement19.0%Biotechs Industry Average Movement10.9%Market Average Movement8.8%10% most volatile stocks in KR Market16.1%10% least volatile stocks in KR Market4.5%安定した株価: A308080の株価は、 KR市場と比較して過去 3 か月間で変動しています。時間の経過による変動: A308080の weekly volatility ( 19% ) は過去 1 年間安定していますが、依然としてKRの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201364Kim Tai Gyuwww.vigencell.comViGenCell社は免疫細胞治療に特化している。抗原特異的キラーT細胞を用いてがん細胞を標的として除去するT細胞療法プラットフォームであるViTier、自然免疫キラーT細胞を用いて異常細胞を標的として除去するT細胞遺伝子療法プラットフォームであるViRanger、臍帯血由来の骨髄抑制細胞を分化・増殖させて万能細胞とする免疫抑制細胞療法プラットフォームであるViMedierを開発している。同社は1995年に設立され、韓国のソウルを拠点としている。もっと見るViGenCell Inc. 基礎のまとめViGenCell の収益と売上を時価総額と比較するとどうか。A308080 基礎統計学時価総額₩145.34b収益（TTM）-₩12.56b売上高(TTM)₩278.95m521.0xP/Sレシオ-11.6xPER（株価収益率A308080 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A308080 損益計算書（TTM）収益₩278.95m売上原価₩274.65m売上総利益₩4.30mその他の費用₩12.56b収益-₩12.56b直近の収益報告Mar 31, 2025次回決算日該当なし一株当たり利益（EPS）-612.64グロス・マージン1.54%純利益率-4,502.18%有利子負債／自己資本比率13.0%A308080 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/20 21:01終値2026/06/19 00:00収益2025/03/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ViGenCell Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 19New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩149.4b (US$97.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2025 fiscal period end). Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$181k). Minor Risk Market cap is less than US$100m (₩149.4b market cap, or US$97.1m).
New Risk • May 16New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2025. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2025 fiscal period end). Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$186k).
お知らせ • Feb 27ViGenCell Inc., Annual General Meeting, Mar 26, 2026ViGenCell Inc., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 222, banpo-daero, seocho-gu, seoul South Korea
New Risk • Feb 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩125.7b (US$87.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$193k). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (₩125.7b market cap, or US$87.1m).
New Risk • Dec 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$190k). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (₩125.6b market cap, or US$85.5m).
New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩279m revenue, or US$189k). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩93.1b market cap, or US$63.2m).
New Risk • Jun 19New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩149.4b (US$97.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2025 fiscal period end). Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$181k). Minor Risk Market cap is less than US$100m (₩149.4b market cap, or US$97.1m).
New Risk • May 16New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2025. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2025 fiscal period end). Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$186k).
お知らせ • Feb 27ViGenCell Inc., Annual General Meeting, Mar 26, 2026ViGenCell Inc., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 222, banpo-daero, seocho-gu, seoul South Korea
New Risk • Feb 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩125.7b (US$87.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$193k). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (₩125.7b market cap, or US$87.1m).
New Risk • Dec 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$190k). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (₩125.6b market cap, or US$85.5m).
New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩279m revenue, or US$189k). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩93.1b market cap, or US$63.2m).
New Risk • Oct 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Revenue is less than US$1m (₩279m revenue, or US$197k). Minor Risk Market cap is less than US$100m (₩73.0b market cap, or US$51.5m).
分析記事 • Jul 15Does ViGenCell (KOSDAQ:308080) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Risk • Jul 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩279m revenue, or US$203k). Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$100m (₩77.7b market cap, or US$56.4m).
分析記事 • Feb 28Is ViGenCell (KOSDAQ:308080) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
お知らせ • Feb 27ViGenCell Inc., Annual General Meeting, Mar 27, 2025ViGenCell Inc., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 222, banpo-daero, seocho-gu, seoul South Korea
お知らせ • Jan 25Gaeun Global Co.,Ltd completed the acquisition of 11.36% stake in ViGenCell Inc. (KOSDAQ:A308080) from Boryung Corporation (KOSE:A003850).Gaeun Global Co.,Ltd agreed to acquire 11.36% stake in ViGenCell Inc. (KOSDAQ:A308080) from Boryung Corporation (KOSE:A003850) for KRW 7.9 billion on December 18, 2024. Gaeun Global Co.,Ltd completed the acquisition of 11.36% stake in ViGenCell Inc. (KOSDAQ:A308080) from Boryung Corporation (KOSE:A003850) on January 23, 2025.
New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩56m revenue, or US$39k). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩65.3b market cap, or US$46.0m).
分析記事 • Nov 15Is ViGenCell (KOSDAQ:308080) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Jul 25Is ViGenCell (KOSDAQ:308080) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
